Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.16
ZTS's Cash to Debt is ranked lower than
52% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ZTS: 0.16 )
ZTS' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.16

Equity to Asset 0.21
ZTS's Equity to Asset is ranked lower than
52% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ZTS: 0.21 )
ZTS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.69
Current: 0.21

0.12
0.69
Interest Coverage 7.03
ZTS's Interest Coverage is ranked higher than
55% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. ZTS: 7.03 )
ZTS' s 10-Year Interest Coverage Range
Min: 2.3   Max: 22.42
Current: 7.03

2.3
22.42
F-Score: 6
Z-Score: 4.15
M-Score: -2.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.56
ZTS's Operating margin (%) is ranked higher than
90% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. ZTS: 19.56 )
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53   Max: 17.41
Current: 19.56

-4.53
17.41
Net-margin (%) 11.91
ZTS's Net-margin (%) is ranked higher than
83% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. ZTS: 11.91 )
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62   Max: 11.05
Current: 11.91

-3.62
11.05
ROE (%) 51.24
ZTS's ROE (%) is ranked higher than
99% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. ZTS: 51.24 )
ZTS' s 10-Year ROE (%) Range
Min: 11.26   Max: 20.3
Current: 51.24

11.26
20.3
ROA (%) 8.71
ZTS's ROA (%) is ranked higher than
88% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. ZTS: 8.71 )
ZTS' s 10-Year ROA (%) Range
Min: 7.28   Max: 8.58
Current: 8.71

7.28
8.58
ROC (Joel Greenblatt) (%) 32.33
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. ZTS: 32.33 )
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88   Max: 36.32
Current: 32.33

25.88
36.32
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ZTS Guru Trades in Q4 2013

Jim Simons 779,000 sh (New)
Paul Tudor Jones 6,200 sh (New)
Lee Ainslie 7,635,025 sh (+2021.15%)
George Soros 2,495,329 sh (+54.13%)
Mario Gabelli 282,960 sh (+15.61%)
Jean-Marie Eveillard 6,647,674 sh (+13.77%)
John Keeley 81,582 sh (+0.08%)
Ruane Cunniff 173,973 sh (unchged)
Vanguard Health Care Fund 8,412,017 sh (unchged)
Robert Olstein 160,000 sh (unchged)
George Soros 186,000 sh (unchged)
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
Pioneer Investments 1,924,824 sh (-0.02%)
RS Investment Management 2,234,184 sh (-1.42%)
Steven Cohen 4,749,899 sh (-26.65%)
» More
Q1 2014

ZTS Guru Trades in Q1 2014

Joel Greenblatt 42,374 sh (New)
Paul Tudor Jones 15,774 sh (+154.42%)
George Soros 4,205,043 sh (+68.52%)
Vanguard Health Care Fund 10,421,717 sh (+23.89%)
RS Investment Management 2,687,539 sh (+20.29%)
Robert Olstein 178,000 sh (+11.25%)
Lee Ainslie Sold Out
Ruane Cunniff 173,553 sh (-0.24%)
Pioneer Investments 1,913,056 sh (-0.61%)
John Keeley 79,108 sh (-3.03%)
Mario Gabelli 260,552 sh (-7.92%)
Jean-Marie Eveillard 3,763,386 sh (-43.39%)
Jim Simons 163,303 sh (-79.04%)
Steven Cohen 683,462 sh (-85.61%)
» More
Q2 2014

ZTS Guru Trades in Q2 2014

Pioneer Investments 2,254,815 sh (+17.86%)
George Soros 4,386,635 sh (+4.32%)
Vanguard Health Care Fund 10,798,417 sh (+3.61%)
Ruane Cunniff 173,562 sh (+0.01%)
Robert Olstein 178,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
RS Investment Management 2,548,819 sh (-5.16%)
John Keeley 74,504 sh (-5.82%)
Mario Gabelli 242,980 sh (-6.74%)
Joel Greenblatt 33,034 sh (-22.04%)
Jean-Marie Eveillard 2,177,060 sh (-42.15%)
» More
Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Robert Olstein 178,000 sh (unchged)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Joel Greenblatt Sold Out
Jean-Marie Eveillard 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
Pioneer Investments 2,203,980 sh (-2.25%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Bill Ackman 2014-09-30 New Buy1.5%$31.79 - $37.2 $ 43.1526%5536862
Joel Greenblatt 2014-09-30 Sold Out 0.01%$31.79 - $37.2 $ 43.1526%0
Jean-Marie Eveillard 2014-06-30 Reduce -42.15%0.12%$28.4 - $32.89 $ 43.1541%2177060
Joel Greenblatt 2014-06-30 Reduce -22.04%$28.4 - $32.89 $ 43.1541%33034
Lee Ainslie 2014-03-31 Sold Out 3.2%$29.01 - $32.69 $ 43.1541%0
George Soros 2014-03-31 Add 68.52%0.49%$29.01 - $32.69 $ 43.1541%4205043
Jean-Marie Eveillard 2014-03-31 Reduce -43.39%0.26%$29.01 - $32.69 $ 43.1541%3763386
Vanguard Health Care Fund 2014-03-31 Add 23.89%0.16%$29.01 - $32.69 $ 43.1541%10421717
Joel Greenblatt 2014-03-31 New Buy0.02%$29.01 - $32.69 $ 43.1541%42374
Lee Ainslie 2013-12-31 Add 2021.15%3.05%$31.04 - $33.22 $ 43.1535%7635025
George Soros 2013-12-31 Add 54.13%0.24%$31.04 - $33.22 $ 43.1535%2495329
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 38.50
ZTS's P/E(ttm) is ranked higher than
78% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. ZTS: 38.50 )
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31   Max: 42.59
Current: 38.5

27.31
42.59
P/B 15.90
ZTS's P/B is ranked higher than
50% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. ZTS: 15.90 )
ZTS' s 10-Year P/B Range
Min: 12.65   Max: 24.37
Current: 15.9

12.65
24.37
P/S 4.58
ZTS's P/S is ranked higher than
68% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. ZTS: 4.58 )
ZTS' s 10-Year P/S Range
Min: 3.11   Max: 4.77
Current: 4.58

3.11
4.77
PFCF 60.80
ZTS's PFCF is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ZTS: 60.80 )
ZTS' s 10-Year PFCF Range
Min: 25.57   Max: 90.29
Current: 60.8

25.57
90.29
EV-to-EBIT 25.61
ZTS's EV-to-EBIT is ranked higher than
80% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. ZTS: 25.61 )
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 28.1
Current: 25.61

20.9
28.1
PEG 1.34
ZTS's PEG is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ZTS: 1.34 )
ZTS' s 10-Year PEG Range
Min: 0   Max: 9973.9
Current: 1.34

0
9973.9
Current Ratio 3.36
ZTS's Current Ratio is ranked higher than
79% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. ZTS: 3.36 )
ZTS' s 10-Year Current Ratio Range
Min: 2.29   Max: 3.47
Current: 3.36

2.29
3.47
Quick Ratio 1.97
ZTS's Quick Ratio is ranked higher than
73% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ZTS: 1.97 )
ZTS' s 10-Year Quick Ratio Range
Min: 1.35   Max: 1.97
Current: 1.97

1.35
1.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.67
ZTS's Dividend Yield is ranked lower than
75% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. ZTS: 0.67 )
ZTS' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.94
Current: 0.67

0.21
0.94
Dividend Payout 0.25
ZTS's Dividend Payout is ranked higher than
85% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ZTS: 0.25 )
ZTS' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.31
Current: 0.25

0.22
0.31
Yield on cost (5-Year) 0.70
ZTS's Yield on cost (5-Year) is ranked lower than
75% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. ZTS: 0.70 )
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.94
Current: 0.7

0.21
0.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
ZTS's Price/Median PS Value is ranked higher than
71% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. ZTS: 1.30 )
ZTS' s 10-Year Price/Median PS Value Range
Min: 0.89   Max: 1.1
Current: 1.3

0.89
1.1
Earnings Yield (Greenblatt) 3.70
ZTS's Earnings Yield (Greenblatt) is ranked higher than
80% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ZTS: 3.70 )
ZTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 4.8
Current: 3.7

3.6
4.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK